Impact of Skeletal Muscle Quality and Loss on the Outcome of Liver Transplantation

CT imaging-based skeletal muscle assessment has been found to predict the outcomes of many diseases. Previous evidence revealed that pre-transplant muscle quality and post-transplant muscle loss were associated with transplant outcomes. However, there is no prospective study supporting the aforementioned conclusions. This study aims to prospectively include liver transplant patients from multiple transplant centers, collecting their pre-transplant CT images as well as post-transplant CT images at specific time points. The objective is to further explore and clarify the correlation between skeletal muscle assessment and the prognosis of liver transplant patients. The goal is to provide guidance for peri-transplant health monitoring and disease intervention for liver transplant patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Liver Transplantation Atrophy Muscle Loss Muscle Quality Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients undergoing deceased donor liver transplantation (DDLT) for the first time

Exclusion criteria

Pediatric transplants
Presence of portal vein tumor thrombus according to imageing before transplantation
Presence of macrovascular invasion according to imageing before transplantation
Re-transplants
Multi-organ transplants
Patients who died within 30 days after transplantation
Patients diagnosed with skeletal muscle diseases (e.g. muscle atrophy)
Patients with serious medical conditions such as heart failure, persistent infection, and renal insufficiency.

Treatment and study plan

Primary outcomes

Postoperative mortality

Time frame: 2024.1.1-2027.1.1
Postoperative recurrence of liver cancer

Time frame: 2024.1.1-2027.1.1

Specifically for the included patients who undergo liver transplantation for liver cancer

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Collaborators

First Affiliated Hospital of Zhejiang University
Huashan Hospital
Shulan (Hangzhou) Hospital
The Affiliated Hospital of Qingdao University
West China Hospital

Registry information

Important dates

Study start: 2024
Primary completion: 2027
Study completion: 2029
First posted: Jan 3, 2024
Registry last updated: Jan 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed